Cas:127958-10-5 2-Methyl-4-phenyl-5-pyrimidinecarboxylic acid manufacturer & supplier

Chemical Name:2-Methyl-4-phenyl-5-pyrimidinecarboxylic acid

CAS.NO:127958-10-5

Synonyms:2-Methyl-4-phenylpyrimidine-5-carboxylic acid;2-Methyl-4-phenyl-5-pyrimidinecarboxylic acid;5-Pyrimidinecarboxylic acid, 2-methyl-4-phenyl-;2-methyl-4-phenyl-pyrimidine-5-carboxylic acid;5-Pyrimidinecarboxylicacid,2-methyl-4-phenyl

Molecular Formula:C₁₂H₁₀N₂O₂

Molecular Weight:214.220

HS Code:2933599090

Physical and Chemical Properties:

Melting point:216-217ºC

Boiling point:375.2±22.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.608

PSA:63.08000

Exact Mass:214.074234

LogP:1.42

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Methyl-4-phenylpyrimidine-5-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Pyrimidinecarboxylicacid,2-methyl-4-phenyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Pyrimidinecarboxylicacid,2-methyl-4-phenyl Use and application,5-Pyrimidinecarboxylic acid, 2-methyl-4-phenyl- technical grade,usp/ep/jp grade.

Related News: Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 2-Methyl-4-phenyl-5-pyrimidinecarboxylic acid manufacturer Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. 2-Methyl-4-phenyl-5-pyrimidinecarboxylic acid supplier Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 2-Methyl-4-phenyl-5-pyrimidinecarboxylic acid vendor Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 2-Methyl-4-phenyl-5-pyrimidinecarboxylic acid factory Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease.